Voyager Therapeutics (VYGR) EBIAT (2016 - 2025)
Voyager Therapeutics (VYGR) has disclosed EBIAT for 11 consecutive years, with -$27.4 million as the latest value for Q4 2025.
- Quarterly EBIAT rose 20.47% to -$27.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$119.7 million through Dec 2025, down 84.18% year-over-year, with the annual reading at -$119.7 million for FY2025, 84.18% down from the prior year.
- EBIAT hit -$27.4 million in Q4 2025 for Voyager Therapeutics, up from -$27.9 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $124.0 million in Q1 2023 to a low of -$34.5 million in Q4 2024.
- Historically, EBIAT has averaged -$8.5 million across 5 years, with a median of -$21.9 million in 2021.
- Biggest five-year swings in EBIAT: crashed 513.84% in 2022 and later surged 681.85% in 2023.
- Year by year, EBIAT stood at $5.7 million in 2021, then plummeted by 513.84% to -$23.6 million in 2022, then surged by 338.7% to $56.4 million in 2023, then tumbled by 161.15% to -$34.5 million in 2024, then rose by 20.47% to -$27.4 million in 2025.
- Business Quant data shows EBIAT for VYGR at -$27.4 million in Q4 2025, -$27.9 million in Q3 2025, and -$33.4 million in Q2 2025.